Literature DB >> 6248192

Ectopic hormones in lung cancer patients at diagnosis and during therapy.

C Gropp, K Havemann, A Scheuer.   

Abstract

In roughly 10 patients with lung cancer of various histologic types, the levels of hormones adrenocorticotropin (ACTH), calcitonin, parathormone, beta-choriogonadotropin (HCG), human placental lactogen (HPL), growth hormone (HGH), and prolactin were determined by radioimmunoassay. The ACTH level was elevated in 30% of patients with oat cell carcinoma and in 26% of patients with large cell carcinoma. Calcitonin levels were increased in 48% of patients with oat cell carcinoma. Elevated levels of HCG were found in 33% of patients with oat cell carcinoma, in 26% of patients with large cell carcinoma, and in 19% of patients with squamous cell carcinoma. Parathormone was increased in 32% of patients with squamous cell carcinoma in 27% of patients with oat cell carcinoma, and in a few patients with large cell carcinoma. Prolactin, HCG and HPL were present only in single cases. Elevated levels of at least one hormone were found in 65.2% of all patients, and in 78% of the patients with oat cell carcinoma. Serial determinations of ACTH and calcitonin showed that these hormones are useful for monitoring therapy in lung patients. There was no relation between hormone levels and the clinical stage of disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248192     DOI: 10.1002/1097-0142(19800715)46:2<347::aid-cncr2820460223>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.

Authors:  Shamim Ejaz; Rena Vassilopoulou-Sellin; Naifa L Busaidy; Mimi I Hu; Steven G Waguespack; Camilo Jimenez; Anita K Ying; Maria Cabanillas; Maher Abbara; Mouhammed Amir Habra
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

2.  Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma.

Authors:  A R Gibbs; R Harach; J C Wagner; B Jasani
Journal:  Thorax       Date:  1985-02       Impact factor: 9.139

Review 3.  Studying lung cancer in the laboratory: 3--Use of cell lines to investigate the biology of lung cancer.

Authors:  R J Fergusson; J F Smyth
Journal:  Thorax       Date:  1987-12       Impact factor: 9.139

4.  Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation.

Authors:  J M Davison; E A Shiells; P R Philips; M D Lindheimer
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

Review 5.  [Short-term induction and cyclic maintenance therapy in inoperable small cell bronchial cancer].

Authors:  N Niederle; W Krischke; U Schulz; C G Schmidt; S Seeber
Journal:  Klin Wochenschr       Date:  1982-08-16

Review 6.  Response of paraneoplastic syndromes to antineoplastic therapy.

Authors:  M Markman
Journal:  West J Med       Date:  1986-05

Review 7.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

8.  Adrenocorticotropin, calcitonin, and antidiuretic hormone as tumor markers in patients with bronchogenic carcinoma of various histological types.

Authors:  W Winkelmann; U Deuss; B Allolio; W Hummerich; D Kaulen; H Brosch; A Guyot; C Arnold
Journal:  Klin Wochenschr       Date:  1984-11-02

9.  Biological markers in human lung carcinoma: an immunopathological study of six antigens.

Authors:  H R Harach; M Skinner; A R Gibbs
Journal:  Thorax       Date:  1983-12       Impact factor: 9.139

10.  The role of human chorionic gonadotropin beta subunit elevation in small-cell lung cancer patients.

Authors:  M Szturmowicz; E Wiatr; A Sakowicz; J Slodkowska; K Roszkowski; S Filipecki; E R Rowinska-Zakrzewska
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.